Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q3 FY2023 Earnings Presentation
16 slides from Thyrocare Technologies's earnings presentation, Feb 3, 2023
Slide 1: Stock exchange filing letter for results presentation
February 03, 2023 The National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Presentation- unaudited financial results
Slide 2: Thyrocare Technologies Limited Quarter Results – Q3 FY22-23
Thyrocare Technologies Limited Quarter Results – Q3 FY22-23 0
Slide 3: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 1
Slide 4: Continued efforts on focus areas to drive sustainable growth
Continued efforts on focus areas which we highlighted to drive sustainable growth Geography • Pin Expansion: 3950+ active pincodes in Q3 FY23 Expansion • Lab Expansion: Added 3 labs; 1 RPL at Varanasi, Satellite labs in Mumbai and Bangalore; Total 29 labs Customer • Extending our lifestyle Aarogyam
Slide 5: Customer & Doctor Connect – Aarogyam Plus and Pro Series; Awareness Programs
Customer & Doctor Connect – Aarogyam Plus and Pro Series; Awareness Programs Aarogyam Packages Launch Awareness Programs Introduced new packages in the price ranges of Rs. <1200 Diabetes Awareness and between Rs. 2500 to Rs. 4500 For World Diabetes Day 3
Slide 6: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 4
Slide 7: Quarter Health-check
Quarter Health-check YoY Non-Covid Revenue YoY Total Revenue* YoY Radiology Revenue +20% +9% +50% YoY Non-Covid samples YoY Pathology Revenue QoQ Radiology Revenue +47% +6% +11% (5.3 Mn samples in this Q) YoY Covid Revenue QoQ Total Revenue* QoQ Pathology Revenue -94% -5% -6% *Consolidated Revenue 5
Slide 8: YoY Overall Pathology revenue grew despite steep de-growth in COVID business
YoY Overall Pathology revenue grew despite steep de-growth in COVID business Significant growth in Non COVID over last year Strong recovery of Non COVID business in 9M FY23 YoY 9M Non Covid Growth Pathology Revenue (INR Cr) +23% 438.2 361.7 +6% 154.9 5.6 117.2 110.2 0.9 15.3 +20% +20% 338.6 109.0 27
Slide 9: Our core business verticals continue to grow YoY
Our core business verticals continue to grow YoY – Franchise business and Partnerships main drivers of growth Non COVID Diagnostics Services Revenue (Rs Cr) Non COVID Diagnostics Services Workload (Lakhs) 39 72 37 36 68 67 65 33 33 60 62 60 30 28 18 17 38 38 16 35 31 14 28 25 20 8 8 5 Q1 FY22 Q2 FY2
Slide 10: Income Statement – Pathology
Income Statement – Pathology Quarter Q Variance % Pathology revenue increased INR crore Q3 FY22 Q2 FY23 Q3 FY23 Seq. YOY 6% Y-o-Y with Non Covid Revenue from operations 110.20 125.23 117.17 -6% 6% revenue increase at 20% YoY.. Cost of materials consumed/ sold (29.00) (39.46) (39.01) -1% 35% Gross ma
Slide 11: Income Statement – Radiology
Income Statement – Radiology Quarter Q Variance % Revenue from imaging INR crore Q3 FY22 Q2 FY23 Q3 FY23 Seq. YOY services grew 11% Q-o-Q on Revenue from operations 7.26 9.74 10.86 11% 50% account of scale up of FDG Cost of materials consumed/ sold (1.00) (1.67) (1.84) 10% 84% Sales and Surat centre
Slide 12: Income Statement – Consolidated
Income Statement – Consolidated Quarter Q Variance % Diagnostics revenue increased INR crore Q3 FY22 Q2 FY23 Q3 FY23 Seq. YOY 9% Y-o-Y with Non – Covid Revenue from operations 117.40 134.97 128.03 -5% 9% Revenue increase at 20% Y-o-Y Cost of materials consumed/ sold (30.00) (41.12) (40.86) -1% 36% G
Slide 13: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 11
Slide 14: Strategy to be the partner of choice for diagnostics to all healthcare providers
We continue with our strategy to be the partner of choice for diagnostics to all healthcare providers 61% 33% Franchise Partnerships + B2G -Mom & Pop collection centers -Online diagnostics aggregators -23 Labs -Local labs -Healthcare platforms -Lab within 200Kms of -Nursing homes & hospitals -Employ
Slide 15: We continue to execute against our strategy shared in May
We continue to execute against our strategy shared in May – will remain focused on the execution against this agenda + 1 Serve Pharmeasy Online customer base of 2.1 5 Continue to improve our value proposition to our M quarterly transacting users franchisee network, expand aggressively 2 Partner with
Slide 16: Thank You
Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development,
Thyrocare Technologies — Q3 FY2023 Earnings Presentation on 6ix